Does Cosentyx Lose Effectiveness Over Time?
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, maintains efficacy with continuous use in most patients. Clinical trials show sustained response rates over 5 years, with PASI 90 (90% skin clearance) achieved by 70-80% of psoriasis patients at year 5 on 300 mg dosing.[1][2] No widespread tachyphylaxis (rapid tolerance) occurs, unlike some biologics.
What Do Long-Term Studies Show?
In the SCULPTURE extension trial, 76% of psoriasis patients retained PASI 75 at week 260 (5 years).[1] For ankylosing spondylitis, the PREVENT trial extension reported ASAS40 response in 70% at year 2, stable through year 5.[3] Real-world data from registries like BADBIR confirm durability, with <10% discontinuation due to loss of efficacy annually.[4]
Why Might Efficacy Seem to Wane for Some Patients?
About 10-20% of patients experience secondary failure after 1-3 years, often due to anti-drug antibodies (5-10% incidence, mostly low-titer and non-neutralizing).[2][5] Other factors include disease progression, infections, or non-adherence. Switching to another IL-17 inhibitor like bimekizumab restores response in many cases.[6]
How Common Are Anti-Drug Antibodies?
Seroconversion occurs in 10% of psoriasis patients by year 2, but impacts efficacy in <5%.[2] Continuous use does not increase antibody rates over time; they peak early.
Can You Prevent or Manage Loss of Response?
Dose escalation (e.g., from 150 mg to 300 mg) or interval shortening helps 40-60% of partial responders.[7] Guidelines recommend checking for antibodies or comorbidities before switching. No Cosentyx patents directly address tolerance (U.S. Patent 7,807,155 expires 2028; check DrugPatentWatch.com for updates).[8]
[1] https://www.nejm.org/doi/full/10.1056/NEJMoa1314258
[2] Langley RG et al. J Am Acad Dermatol. 2017;76:864-872.
[3] Deodhar A et al. Rheumatology. 2020;59:3324-3333.
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034741/
[5] Novartis Cosentyx Label (FDA). 2023.
[6] Reich K et al. Lancet. 2021;397:487-498.
[7] Papp K et al. Dermatol Ther. 2018;31:e12795.
[8] https://www.drugpatentwatch.com/p/tradename/COSENTYX